Core Viewpoint - Analysts project AbbVie (ABBV) will report quarterly earnings of $2.40 per share, a 3.9% increase year over year, with revenues expected to reach $12.91 billion, reflecting a 4.8% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 0.8% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings estimates are crucial for predicting investor actions, as empirical research shows a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Net Revenue- Botox Cosmetic- Total' at $576.62 million, down 8.9% year over year [5]. - 'Net Revenue- Imbruvica' is projected to be $676.15 million, reflecting a decrease of 19.3% from the prior-year quarter [5]. - 'Net Revenue- Eye Care- Total' is expected to be $531.41 million, indicating a slight decline of 1.2% [5]. - 'Net Revenue- Juvederm Collection- Total' is forecasted at $253.59 million, down 14.6% from the year-ago quarter [6]. - 'Net Revenue- Creon- US' is estimated at $267.00 million, a decrease of 6.3% year over year [6]. - 'Net Revenue- Rinvoq- International' is projected to reach $504.96 million, an increase of 37.2% from the prior-year quarter [6]. - 'Net Revenue- Rinvoq- US' is expected to be $1.09 billion, reflecting a significant increase of 50.2% year over year [7]. - 'Net Revenue- Humira- International' is estimated at $422.30 million, down 15.4% from the prior-year quarter [7]. - 'Net Revenue- Humira- US' is projected at $898.84 million, indicating a substantial decline of 49.3% year over year [7]. - 'Net Revenue- Immunology- Skyrizi- International' is expected to be $507.22 million, up 44.1% year over year [8]. - 'Net Revenue- Immunology- Skyrizi- US' is projected at $2.69 billion, reflecting a 62.3% increase year over year [8]. - The consensus estimate for 'Geographic Revenues- International' stands at $3.42 billion, indicating a 4.5% increase from the prior-year quarter [9]. Stock Performance - Over the past month, AbbVie shares have returned -18.7%, compared to the Zacks S&P 500 composite's -8.9% change [9].

Core Viewpoint - Matador Resources (MTDR) is expected to report quarterly earnings of $1.71 per share, with revenues projected at $957.5 million, indicating a year-over-year revenue increase of 21.6% [1] Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 11%, reflecting analysts' reassessment of their initial forecasts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Analysts predict 'Revenues- Third-party midstream services revenues' to be $54.21 million, a year-over-year increase of 67.5% [5] - 'Revenues- Oil and natural gas revenues' are expected to reach $857.30 million, reflecting a year-over-year change of 21.9% [5] - The consensus estimate for 'Revenues- Sales of purchased natural gas' is $54.80 million, indicating a year-over-year increase of 10.8% [5] Production Volumes - The 'Average Daily Production Volumes - Total oil equivalent' is projected to be 196,169 million barrels of oil equivalent, up from 149,760 million barrels of oil equivalent reported in the same quarter last year [6] - 'Average Daily Production Volumes - Oil' is expected to reach 114,841.60 BBL/D, compared to 84,777 BBL/D in the previous year [6] - 'Average Daily Production Volumes - Natural gas' is anticipated to be 488.42 million cubic feet, up from 389.9 million cubic feet reported last year [7] Sales Prices - 'Average Sales Prices - Oil, with realized derivatives' is expected to be $71.78, down from $77.58 in the same quarter last year [7] - 'Average Sales Prices - Oil without realized derivatives' is projected at $71.46, compared to $77.58 reported in the same quarter last year [8] Stock Performance - Over the past month, Matador shares have declined by 24.4%, while the Zacks S&P 500 composite has decreased by 8.9% [8] - Matador holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the near term [8]

Core Viewpoint - Wall Street analysts anticipate a slight decline in Merit Medical's quarterly earnings per share, while revenues are expected to show growth compared to the previous year [1]. Earnings Estimates - Analysts expect Merit Medical (MMSI) to report earnings of $0.75 per share, reflecting a year-over-year decline of 2.6% [1]. - Revenue is projected to be $352.33 million, indicating an increase of 8.9% from the same quarter last year [1]. - The consensus EPS estimate has been revised down by 0.1% in the last 30 days, indicating a reassessment by covering analysts [1][2]. Revenue Projections - Revenue from 'Cardiovascular- Peripheral Intervention' is estimated to reach $141.95 million, a year-over-year increase of 5.4% [4]. - 'Cardiovascular- Cardiac Intervention' revenue is expected to be $98.79 million, reflecting an 8.9% increase year over year [4]. - 'Endoscopy' revenue is projected at $17.89 million, showing a significant year-over-year increase of 76.5% [5]. - 'Cardiovascular- OEM' revenue is expected to be $43.84 million, indicating an 11.6% increase from the previous year [5]. - Total 'Cardiovascular' revenue is projected to reach $334.45 million, reflecting a 6.7% year-over-year change [5]. Geographic Sales Estimates - 'Geographic Sales- United States' is estimated at $208.66 million, suggesting a year-over-year increase of 12.1% [6]. - 'Geographic Sales- International' is projected to be $143.33 million, indicating a 4.3% increase year over year [6]. Stock Performance - Over the past month, Merit Medical shares have decreased by 10.6%, compared to a 5.6% decline in the Zacks S&P 500 composite [7]. - Currently, MMSI holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [7].

Core Viewpoint - Knight-Swift Transportation Holdings (KNX) is expected to report quarterly earnings of $0.25 per share, reflecting a year-over-year increase of 108.3%, while revenues are anticipated to decline by 0.9% to $1.81 billion [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 12.5%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue and Key Metrics - Analysts estimate 'Revenue, excluding truckload and LTL fuel surcharge' at $1.60 billion, a year-over-year change of -0.8% [5]. - The 'Truckload and LTL fuel surcharge' is projected to reach $185.70 million, down 11.4% from the previous year [5]. - 'Operating revenue- LTL' is expected to be $337.40 million, reflecting a year-over-year increase of 19.6% [6]. - The consensus for 'Revenue, excluding fuel surcharge and intersegment transactions- Truckload Segment' is $1.05 billion, indicating a decline of 3.7% year-over-year [6]. Operating Ratios - The average 'Operating Ratio' is projected at 95.7%, improving from 98.9% in the same quarter last year [6]. - The 'Adjusted Operating Ratio' is expected to be 94.7%, compared to 96.8% in the previous year [7]. - For 'Adjusted Operating Ratio - Truckload', the estimate is 95.3%, down from 97.3% year-over-year [7]. - The 'Adjusted Operating Ratio - LTL' is projected at 93.4%, compared to 90% in the same quarter last year [8]. - The 'Adjusted Operating Ratio - Logistics' is expected to be 93.7%, down from 97.1% in the previous year [8]. Operational Metrics - The consensus for 'Average tractors - Truckload' is 21,818, down from 23,314 year-over-year [9]. - 'Load count - Intermodal' is expected to reach 38,120, an increase from 33,647 in the previous year [9]. - The 'Average revenue per load - Intermodal' is projected at $2,684.32, compared to $2,615 last year [9]. Market Performance - Knight-Swift shares have returned -11.3% over the past month, underperforming the Zacks S&P 500 composite, which declined by -5.6% [9].

Core Viewpoint - Analysts forecast Discover (DFS) will report quarterly earnings of $3.32 per share, reflecting a year-over-year increase of 201.8%, with revenues expected to be $4.21 billion, showing no change from the previous year [1] Earnings Estimates - Over the last 30 days, there has been a downward revision of 1.4% in the consensus EPS estimate for the quarter, indicating a collective reconsideration by analysts [2] - Changes in earnings estimates are crucial for predicting potential investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock price performance [3] Key Metrics Forecast - Analysts predict 'Net Interest Margin' will reach 11.7%, up from 11% year-over-year [5] - 'Operating Efficiency' is estimated at 39.7%, down from 54.9% year-over-year [5] - 'Credit Card Loans - Discover Card Sales Volume' is expected to be $49.75 billion, compared to $50.14 billion in the same quarter last year [5] - 'Net Principal Charge-off Rate' is projected at 5.1%, up from 4.9% year-over-year [6] - 'Credit Card Loans - Total Discover Card Volume' is expected to be $52.52 billion, down from $53.24 billion year-over-year [6] - 'Network Volume - Total Payment Services' is forecasted to reach $105.02 billion, compared to $100.32 billion in the same quarter last year [7] - 'Tier 1 Risk Based Capital Ratio' is expected to be 15.4%, up from 11.7% year-over-year [7] - 'Transactions Processed on Networks - Total' is estimated at $3.43 billion, compared to $3.20 billion last year [8] - 'Network Volume - Diners Club International' is forecasted to reach $10.83 billion, up from $10.18 billion year-over-year [8] - 'Network Volume - Network Partners' is estimated at $9.45 billion, down from $11.07 billion year-over-year [9] - 'Network Volume - PULSE Network' is expected to reach $85.72 billion, up from $79.07 billion year-over-year [9] - 'Transactions Processed on Networks - Discover Network' is projected at $909.38 million, compared to $883 million last year [10] Stock Performance - Shares of Discover have shown returns of -3.2% over the past month, compared to the Zacks S&P 500 composite's -5.6% change, with a Zacks Rank 3 (Hold) indicating expected performance in line with the overall market [11]

Core Insights - Xcel Energy (XEL) is expected to report quarterly earnings of $0.96 per share, a 9.1% increase year-over-year, with revenues projected at $3.93 billion, reflecting a 7.8% increase compared to the same period last year [1] Earnings Estimates - There has been a downward revision of 5.6% in the consensus EPS estimate over the last 30 days, indicating analysts' reassessment of their initial forecasts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - The consensus estimate for 'Operating revenues- Electric and natural gas' is $3.91 billion, representing a 7.9% increase from the previous year [5] - 'Operating revenues- Other' is expected to be -$60.80 million, indicating a significant decline of 364.3% year-over-year [5] - 'Operating revenues- Natural Gas' is forecasted to reach $921.31 million, suggesting a slight decrease of 2.1% year-over-year [5] - Analysts predict 'Operating revenues- Electric' will likely be $2.99 billion, reflecting an 11.4% increase year-over-year [6] Market Performance - Xcel shares have returned +1.5% over the past month, contrasting with the Zacks S&P 500 composite's -5.6% change [6] - Xcel holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market in the near future [6]

Core Viewpoint - Weyerhaeuser (WY) is expected to report a quarterly earnings decline of 25% year-over-year, with earnings per share (EPS) projected at $0.12 and revenues estimated at $1.76 billion, reflecting a decrease of 1.9% compared to the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised 3.8% lower in the last 30 days, indicating a reevaluation by analysts [1][2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [2] Revenue Projections - Analysts estimate 'Revenue- Wood Products' to be $1.29 billion, indicating a year-over-year decline of 0.9% [3] - 'Revenue- Real Estate & ENR' is projected at $88.20 million, suggesting a significant year-over-year decrease of 17.6% [4] Segment Performance - The 'Wood Products Segment- Structural lumber- Third party net sales' is expected to reach $508.94 million, reflecting a year-over-year increase of 9.7% [4] - 'Wood Products Segment- Oriented Strand Board (square feet 3/8')- Third party net sales' is forecasted at $235.78 million, indicating a decline of 7.5% year-over-year [5] Sales Realizations - 'Delivered Logs Third Party Sales Realizations (per ton) - West' is expected to be $120.89, slightly down from $121.06 year-over-year [5] - 'Wood Products - Medium Density Fiberboard (square feet 3/4') - Third party sales realizations' is projected at $1,170.68, down from $1,183 year-over-year [6] Sales Volumes - 'Delivered Logs Third Party Sales Volumes (tons) - West' is estimated at 1,469.10 KTon, up from 1,452 KTon in the same quarter last year [7] - 'Delivered Logs Third Party Sales Volumes (tons) - South' is projected at 4,091.78 KTon, slightly up from 4,089 KTon year-over-year [7] - 'Delivered Logs Third Party Sales Volumes (tons) - North' is expected to be 176.12 KTon, up from 175 KTon in the same quarter last year [8] Overall Market Performance - Over the past month, Weyerhaeuser shares have declined by 11.6%, compared to a 5.6% decline in the Zacks S&P 500 composite [10] - The company holds a Zacks Rank 3 (Hold), suggesting it will likely perform in line with the overall market in the near term [10]

Core Viewpoint - Analysts expect Old Dominion Freight Line (ODFL) to report quarterly earnings of $1.14 per share, reflecting a year-over-year decline of 14.9%, with revenues projected at $1.37 billion, down 6.3% from the previous year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 4.4%, indicating a collective reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue and Key Metrics - Analysts estimate 'Total revenue- Other services' to be $13.37 million, showing a year-over-year increase of 0.2% [5]. - 'Total revenue- LTL services' is forecasted to reach $1.35 billion, indicating a decline of 6.5% year-over-year [5]. - The expected 'Operating Ratio' is 76.3%, up from 73.5% in the same quarter last year [5]. LTL Performance Metrics - 'LTL tonnage per day' is projected at 33.40 Kton/D, down from 35.38 Kton/D a year ago [6]. - 'LTL shipments per day' are expected to be 44.47 thousand, compared to 46.93 thousand in the same quarter last year [6]. - 'LTL revenue per hundredweight' is estimated at $32.62, up from $31.98 a year ago [6]. Additional LTL Metrics - 'LTL revenue per hundredweight, excluding fuel surcharges' is projected at $27.84, compared to $26.78 last year [7]. - 'LTL shipments' are expected to reach 2,801, down from 3,004 in the same quarter last year [7]. - 'LTL tons' are forecasted at 2,079.28 KTon, down from 2,264 KTon a year ago [8]. Shipment and Weight Metrics - The average 'LTL weight per shipment' is estimated at 1,484.92 lbs, compared to 1,508 lbs last year [8]. - 'Work days' are projected to be 63.00 days, down from 64 days a year ago [8]. - 'LTL revenue per shipment' is expected to be $483.32, slightly up from $482.24 in the same quarter last year [9]. Stock Performance - Over the past month, shares of Old Dominion have declined by 6.9%, compared to a 5.6% decline in the Zacks S&P 500 composite [9]. - Currently, ODFL holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [10].

Core Viewpoint - Freeport-McMoRan (FCX) is expected to report a decline in quarterly earnings and revenues, with analysts predicting earnings of $0.24 per share, a 25% decrease year-over-year, and revenues of $5.31 billion, reflecting a 16% decline compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been revised upward by 9.8% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Estimates - Analysts estimate 'Revenues- Indonesia' at $1.31 billion, a decrease of 53.6% from the prior-year quarter [5]. - 'Revenues- Molybdenum' are expected to reach $261.94 million, showing an increase of 80.7% year-over-year [5]. - 'Revenues- South America copper mines' are projected at $1.29 billion, indicating a year-over-year increase of 13.9% [5]. - 'Revenues- North America copper mines' are forecasted to be $1.56 billion, reflecting a 3.9% increase year-over-year [6]. Production and Sales Estimates - 'Production in millions of pounds - Molybdenum - South America (Cerro Verde)' is expected to be 5.82 Mlbs, up from 3 Mlbs in the same quarter last year [7]. - 'Production in millions of pounds - Molybdenum - By-product - North America' is estimated at 7.73 Mlbs, compared to 7 Mlbs reported in the same quarter last year [7]. - 'Sales in thousands of Ounces - Gold - North America' are projected at 3.87 Koz, down from 4 Koz in the same quarter last year [8]. - 'Sales in thousands of ounces - Gold - Consolidated basis' are expected to reach 126.13 Koz, significantly lower than 568 Koz reported in the same quarter last year [8]. - 'Sales in thousands of Ounces - Gold - Indonesia' are estimated at 122.25 Koz, down from 564 Koz year-over-year [9]. - 'Sales in millions of pounds - Copper - Total South America' are projected at 281.86 Mlbs, slightly lower than 284 Mlbs reported in the same quarter last year [9]. - 'Sales in millions of pounds - Copper - Indonesia - Grasberg' are expected to be 242.98 Mlbs, down from 493 Mlbs year-over-year [10]. Stock Performance - Freeport-McMoRan shares have decreased by 19.2% over the past month, contrasting with a 6.9% decline in the Zacks S&P 500 composite [11].

Core Viewpoint - Analysts expect Gilead Sciences to report quarterly earnings of $1.73 per share, reflecting a year-over-year increase of 231.1%, with revenues projected at $6.83 billion, up 2.2% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.9% in the past 30 days, indicating a reassessment of initial estimates by covering analysts [1][2]. Revenue and Product Sales Projections - Total product sales are expected to reach $6.75 billion, indicating a year-over-year change of +1.6% [4]. - Royalty contract and other revenues are estimated at $40.04 million, reflecting a +2.7% change from the prior year [4]. - Product Sales for HIV (Genvoya) are projected at $375.96 million, showing a decline of -6.7% year over year [4]. - Product Sales for HIV (Odefsey) are expected to be $294.72 million, down -4.9% from the previous year [5]. - Oncology product sales (Tecartus) are forecasted at $56.12 million, indicating a +2% change [5]. - Liver Disease product sales (Sofosbuvir/Velpatasvir) are estimated at $238.12 million, down -4% from the year-ago quarter [6]. - Other product sales (Other) are projected at $40.07 million, reflecting a significant decline of -32.1% [6]. - Total HIV product sales in the U.S. are expected to reach $3.56 billion, indicating a +4.6% change year over year [7]. Additional Product Sales Insights - Product Sales for HIV (Genvoya) in the U.S. are projected at $299.29 million, down -9.9% from the previous year [7]. - Liver Disease product sales (Vemlidy) are expected to be $96.60 million, reflecting a +1.7% change [8]. - Other product sales (AmBisome) are projected at $11.31 million, down -19.2% from the prior year [8]. - Product Sales for Veklury are expected to be $277.30 million, indicating a -12% change year over year [8]. Stock Performance - Gilead shares have experienced a -1.3% change over the past month, compared to a -6.9% move in the Zacks S&P 500 composite [9].